LEVEL 4 N01AX10

Δραστικές

PROPOFOL

Φάρμακα

  • DRUGBANK - Propofol
  • indication:

    Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.

  • pharmacology:

  • mechanism:

    The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.

  • toxicity:

    Overdosage may increase pharmacologic and adverse effects or cause death. <p>IV LD<sub>50</sub>=53 mg/kg (mice), 42 mg/kg (rats). Oral LD<sub>50</sub> (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)</p>

  • absorprion:

    Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.

  • halflife:

    Initial distribution phase t<sub>1/2α</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2β</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2γ</sub>=1.5-31 hours.

  • roouteelimination:

    It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.

  • volumedistribution:

    * 60 L/kg [healthy adults]

  • clearance:

    * 23 - 50 mL/kg/min * 1.6 - 3.4 L/min [70 Kg adults]